Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Life Sciences (US) files for Parkinson's agent:

This article was originally published in Clinica

Executive Summary

Boston Life Sciences (US) plans to begin a clinical trial with the Parkinson's disease radioimaging agent, Altropane, before the end of this year. An IND (investigational new drug) application has been filed with the FDA. The radiolabelled molecule binds to the dopamine transporter in areas of the brain affected by the disease. Use of Altropane is expected to provide earlier diagnosis of Parkinson's, enabling earlier therapeutic intervention, says chief scientific officer Marc Lanser. Apart from later-stage products obtained through the merger with Greenwich Pharmaceuticals, Altropane is Boston Life Sciences' first product to enter clinical development.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093569

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel